Preclinical studies have further suggested that Poly-ADP-Ribose-Polymerase (PARP) inhibitors, perhaps in combination with PI3-kinase inhibitors, could be useful in endometrial cancer treatment as most endometrial tumors are PTEN-deficient [127,128]. The gene discussed is PTEN; the disease is endometrial cancer.